Close Menu

NEW YORK (360Dx) – Quest Diagnostics today reported 2 percent year-over-year growth in third quarter revenues despite the impact on its business of the hurricanes in Florida and Texas.

For the three months ending Sept. 30, the firm recorded $1.93 billion in total revenues, compared to $1.89 billion in the year-ago quarter. It beat the consensus Wall Street estimate of $1.92 billion in revenues.

Diagnostic information services revenues rose 3 percent year over year to $1.85 billion from $1.80 billion in Q3 2016.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.